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POTENTIAL IMMUNOLOGICAL MARKERS FOR DIAGNOSIS AND THERAPEUTIC  
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SUMMARY
In human toxocariasis, there are few approaches using immunological markers for diagnosis and therapeutic assessment. 
An immunoblot (IB) assay using excretory-secretory Toxocara canis antigen was standardized for monitoring IgG, IgE and IgA 
antibodies in 27 children with toxocariasis (23 visceral, three mixed visceral and ocular, and one ocular form) for 22-116 months after 
chemotherapy. IB sensitivity was 100% for IgG antibodies to bands of molecular weight 29-38, 48-54, 95-116, 121-162, >205 kDa, 
80.8% for IgE to 29-38, 48-54, 95-121, > 205 kDa, and 65.4% for IgA to 29-38, 48-54, 81-93 kDa. Candidates for diagnostic markers 
should be IgG antibodies to bands of low molecular weight (29-38 and 48-54 kDa). One group of patients presented the same antibody 
reactivity to all bands throughout the follow-up study; in the other group, antibodies decayed partially or completely to some or all 
bands, but these changes were not correlated with time after chemotherapy. Candidates for monitoring patients after chemotherapy 
may be IgG antibodies to > 205 kDa fractions, IgA to 29-38, 48-54, 81-93 kDa and IgE to 95-121 kDa. Further identification of 
antigen epitopes related to these markers will allow the development of sensitive and specific immunoassays for the diagnosis and 
therapeutic assessment of toxocariasis.
KEYWORDS: Toxocariasis; Immunoblot assay; Immunoglobulin isotypes; Chemotherapy.
INTRODUCTION
Human toxocariasis, a zoonotic disease caused by larvae of the dog 
ascarid worm, Toxocara canis, and less frequently by those of the cat 
ascarid, Toxocara cati, is found worldwide. In humans, these infecting 
nematode larvae are unable to complete their own developmental life 
cycle and propagation6,7,21. Nevertheless, the larvae migrate through 
different organs, shedding immunogenic glycoproteins, known as 
Toxocara excretory-secretory (TES) antigens. These antigens seem to 
allow larvae to evade and survive under the adverse conditions of the 
host’s immune response5. The clinical symptoms vary as a consequence 
of larvae migration, ranging from asymptomatic forms to those with 
severe organ injuries.
There are two main clinical forms: visceral toxocariasis and ocular 
toxocariasis. Covert toxocariasis has been described as presenting 
non-specific symptoms, such as abdominal pain, headache, cough and 
limb pains. In some instances, neurological manifestations have been 
associated with the presence of Toxocara larvae in the brain9,12.
In the absence of parasitological evidence of infection, 
immunological methods play a relevant role in the diagnosis of 
toxocariasis. The detection of IgG antibodies with the TES-based 
enzyme-linked immunosorbent assay (ELISA) is the preferred 
method3. In follow-up studies after chemotherapy, however, these IgG 
antibodies were observed to be unsuitable as an immunological marker 
for therapeutic assessment, because they remained persistently for 
years4,22, as occurs in most parasitic infections15. In our previous work, 
IgG antibodies detected by ELISA were found to be appropriate for 
serological diagnosis of toxocariasis, and IgE antibodies in conjunction 
with eosinophil counts were helpful parameters for monitoring patients 
after chemotherapy4.
The immunoblot (IB) technique has been shown to be a useful 
tool for many immunologic approaches in different diseases. However, 
there are few follow-up studies in patients after chemotherapy showing 
changes in their IB patterns, according to antibody isotypes and antigen 
fractions. For toxocariasis, there have been attempts to find the most 
suitable antigens or refined antigen epitopes for immunoassays1,11,16. 
There is a need to standardize serodiagnostic criteria and define the 
efficacy of chemotherapy23.
In the present work, patients with toxocariasis were studied before 
and after chemotherapy, in the search for potential immunological 
markers for both diagnosis and therapeutic assessment. The IB patterns 
developed by different antibody isotypes (IgG, IgA and IgE) to TES 
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antigen fractions were investigated, following up patients before and 
after chemotherapy.
This project was approved by the “Comitê de Ética em Pesquisa” 
of the “Instituto de Medicina Tropical de São Paulo” and the “Instituto 
da Criança do Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo”, and by the “Comissão de Ética em Pesquisas 
com Seres Humanos” of the “Instituto de Ciências Biomédicas da 
Universidade de São Paulo”.
MATERIALS AND METHODS
Toxocara canis excretory-secretory antigen (TES): This antigen 
was prepared as described previously by ELEFANT et al.4 from the 
supernatant of a concentrated culture of T. canis larvae, with quality 
control analysis to ensure the reproducibility of the immunologic assays.
Ascaris suum adult worm extract (AWE): Non-specific antibodies 
were removed by serum absorption with AWE. This antigenic extract was 
obtained from A. suum, according to ELEFANT et al.4.
Patients and serum samples: Serum samples from 27 children with 
toxocariasis (23 with the visceral form, three with mixed visceral and 
ocular forms, and one with the ocular form), aged from one to 12 years, 
were collected before and after chemotherapy, annually for a period of 
up to nine years. Patients were treated with thiabendazole (25 mg/kg 
per day) for seven days. In the ocular cases, corticotherapy was also 
administered (prednisone - 1 mg/kg per day). The diagnosis was based 
on clinical, epidemiologic and laboratory findings. Before treatment, 
all patients presented anti-Toxocara IgG antibodies detected by ELISA, 
and all of those with visceral toxocariasis presented eosinophilia ≥ 10%. 
The main clinical symptoms were: pulmonary manifestations in 73.9% 
of the patients, asthma and/or rhinitis in 56.5% and fever in 39.1%. In 
patients with ocular toxocariasis, uveitis and retinal detachment of the 
right eye were the main clinical manifestations. Serum samples from nine 
clinically healthy individuals were collected for use as negative controls.
Immunoblot (IB) procedure: The TES antigen (1.5 mg/mm) was 
fractionated by means of sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) on a 5-15% gel gradient10, and was transferred 
electrophoretically to 0.22-mm pore size nitrocellulose membranes 
(Millipore Corp., Bedford, MA)24. The membranes were cut into strips 3-4 
mm wide, blocked for 30 min at 37 °C with 1% skim milk (Molico, Nestle, 
Araçatuba, São Paulo, Brazil) in phosphate-buffered saline containing 
0.05% Tween 20 (PBS-T). The serum samples were diluted 1/100 for 
IgG-IB and 1/20 for both IgA and IgE-IB with 1% skim milk in PBS-T, 
and strips were incubated for 18 h at 4 °C. All serum samples had been 
pre-absorbed with AWE (25 µg/mL) in PBS-T for 30 min at 37 °C. For 
IgE-IB, serum samples had been also pre-absorbed with RF-absorbent (v/v) 
(Dade Behring, Marburg, Germany) for 18 h at 4 °C, in order to enhance the 
detection of IgE antibodies. After washing, the strips were incubated for two 
h at 37 °C with peroxidase conjugates diluted in 1% skim milk in PBS-T 
as follows: 1/1000 dilution for anti-human IgG (Biolab Diagnostic, Rio 
de Janeiro, Brazil); 1/200 dilution for anti-human IgA (Dako, Denmark); 
and 1/160 dilution of anti-human IgE (Sigma Chemical Co, St Louis, MO, 
USA). Then the strips were washed and treated with 4-chloro-a-naphthol 
(0.05% in methanol) and 0.8 µL/mL H2O2 30%. After 15 min the reaction 
was interrupted with distilled water.
Statistical analysis: Comparisons between proportions were made 
using Fisher’s exact test or chi-square test (c2). Comparisons between 
times when antibodies partially or completely decayed were made by 
Kruskal-Wallis analysis of variance, and the verification of differences 
between groups was evaluated by multiple comparison Student-Newman-
Keuls. The significance levels of the tests were fixed by accepting a type 
1 error of 5% (a = 0.05) (SigmaStat 1.0).
RESULTS
The analysis of the results was conducted on serum samples from 
26 patients (23 visceral + three mixed visceral and ocular). Because we 
studied only one patient with ocular toxocariasis, these results are merely 
descriptive. In the group of nine clinically healthy individuals, specific 
IgG, IgE and IgA antibodies were not detected.
Immunoblot for IgG (IgG-IB): Before treatment, IgG antibodies were 
detected in all patients, corresponding to a 100% sensitivity, predominantly 
to the following TES protein antigens: molecular weight (MW) 29-38, 
48-54, 95-116, 121-162 and > 205 kDa (Fig. 1A). After chemotherapy, 
patients were separated into two groups according to their IgG-IB patterns: 
the first group consisted of 11 (42.3%) patients who presented the same 
IgG antibody reactivity to all bands throughout the period of our study; the 
second group of 15 (57.7%) patients presented changes (i.e., antibodies 
decayed partially or completely to some or all bands) but these changes 
were not correlated with time after chemotherapy (Fisher’s exact test 
p = 1.0) (Table 1). The antibodies to the > 205 kDa bands completely 
disappeared (after two-seven years) in 10 (38.5%) patients, which was 
statistically significant when compared with the other bands (c2, p < 0.05).
Immunoblot for IgE (IgE-IB): Before treatment, specific IgE 
antibodies were found in 21 (80.8%) patients with toxocariasis, and 
these reacted mostly with TES protein antigens of MW 29-38, 48-54, 
66, 95-121 and > 205 kDa (Fig. 1B).These 21 patients were separated 
according to their IgE-IB patterns, similar to the criterion adopted for 
IgG-IB patterns. The first group of six (28.6%) patients had no changes 
in IgE antibody reactivity before and after treatment. In the second 
group, 15 (71.4%) patients presented changes that were not correlated 
with time after chemotherapy (Fisher’s exact test, p = 0.6351) (Table 
1). In 12 (57.1%) patients, antibodies to 95-121 kDa bands completely 
disappeared after two-seven years, but this was not statistically significant 
when compared with the other bands (c2, p = 0.1404).
Immunoblot for IgA (IgA-IB): Before treatment, IgA antibody 
reactivity, observed in 17 (65.4%) patients with toxocariasis, was 
predominantly with TES antigens of MW 29-38, 48-54, 66 and 81-93 
kDa (Fig. 1C). These 17 patients were grouped according to their IgA-IB 
patterns. Two (11.8%) patients had no changes in their post-treatment IgA 
antibody patterns, and 15 (88.2%) patients presented changes that were 
not correlated with time after chemotherapy (Fisher’s exact test, p = 1.0) 
(Table 1). All bands completely disappeared in 12 (70.6%) patients, and 
considering at least one of the three clusters, the antibodies disappeared 
in 15 (88.2%) patients.
Patient with ocular toxocariasis: IgG remained unchanged during 
the 46 months follow-up after chemotherapy, IgA reactivity diminished 
for all bands after 24 months, and IgE antibodies were not detected (Fig. 
1 and Table 1).
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Overall data: IgG, IgA and IgE antibodies to the 66-kDa antigen 
were detected in some patients and remained reactive throughout the 
study, but they are unspecific17. Patients were divided into two groups 
according to the time after chemotherapy when changes in band patterns 
were observed. For IgG and IgE antibodies, the time was four years, 
and for IgA it was two years. In all cases no differences were observed 
(Fisher’s exact test, p > 0.05).
Sixteen (61.5%) patients were reactive to all immunoglobulin 
classes. Two patients showed the same reactivity to all bands throughout 
the study period, and for the other 14, the antibodies decayed partially 
and/or completely for some or all bands. The changes in reactivity (i.e., 
antibodies decayed partially and/or completely) were observed earlier 
for IgA antibodies (Kruskal-Wallis, p = 0.0334) compared with IgG and 
IgE (Student-Newman-Keuls method, p < 0.05).
DISCUSSION
Many immunologic aspects have been investigated in human 
toxocariasis using the IB technique, but there are few studies on 
immunological markers for diagnosis, therapeutic assessment or 
prognosis. Our results show some similarities to and discrepancies 
from reported findings1,11,16, although some studies used different 
immunological approaches for toxocariasis.
Different factors, such as TES antigen preparations, parasite strains, 
and IB technical procedures, seem to influence the results obtained by 
different investigators1.
Before treatment, all patients with toxocariasis (visceral, ocular and 
mixed forms) showed IgG-IB positive results, in agreement with the data 
we have obtained previously by the IgG-ELISA4. In the IgG-IB, sera from 
patients with toxocariasis recognized most of the protein bands, ranging 
from 29 to > 205 kDa. NUNES et al.17 found MW 29-35, 50-55, 97-116, 
200-210 kDa fractions, which were similar to ours in IgG-IB: MW 29-
38, 48-54, 66, 95-116, 121-162 and > 205 kDa. Although BADLEY et 
al.1 considered individual bands (at least 15 bands between 29 and 94 
kDa and four to six bands >200 kDa), our findings were consistent with 
theirs. MAGNAVAL et al.11 observed seven bands (24, 28, 30, 35, 132, 
147 and 200 kDa) and ROLDÁN et al.20 detected 10 bands (24, 28, 30, 
35, 48, 56, 67, 117, 136 and 152 kDa). The intermediate bands (95-116 
and 121-162 kDa) found in the present study were not described by the 
other investigators1,11,17,20, and deserve to be further studied. Technical 
peculiarities used in TES production or the IB procedure may be the 
cause of such differences1,17.
We found antibodies to the 66 kDa band, which was persistently 
reactive and considered unspecific, based on previous data8,14,17. This 
protein has epitopes in common with Ascaris sp. disappearing after 
absorption with A. suum antigen17.
In the follow-up study of patients after chemotherapy, the 
Fig. 1 - IgG, IgA and IgE specific for the main fractions of Toxocara excretory-secretory antigen, in the follow-up of 27 patients with toxocariasis after chemotherapy (22-116 months), by 
immunoblot assay. Toxocariasis patients: 1 to 23, visceral form; 24-26, mixed visceral and ocular; 27, ocular.
RUBINSKY-ELEFANT, G.; HOSHINO-SHIMIZU, S.; JACOB, C.M.A.; SANCHEZ, M.C.A. & FERREIRA, A.W. - Potential immunological markers for diagnosis and therapeutic assessment 
of toxocariasis. Rev. Inst. Med. Trop. Sao Paulo, 53(2): 61-5, 2011. 
64
disappearance of specific IgG antibodies reactive to protein bands > 
205 kDa may be indicative of success of chemotherapy. Therefore, we 
are now studying the performance of specific IgG subclasses (IgG1, 2, 
3 and 4) for these high MW bands.
The IgE-IB patterns developed by patients before treatment were 
similar to those of IgG-IB, except for the absence of 121-162 kDa bands, 
data consistent with those reported by OBWALLER et al.18. Sera from 
two patients with mixed forms and one patient with the ocular form 
of toxocariasis were negative by the IgE-IB, confirming our previous 
negative findings by immunoenzymatic assay (IgE)4. In the ocular form 
of the disease, the detection of specific IgE in aqueous fluid and serum 
has been suggested by some authors13 to give more sensitive results, using 
IgE-IB in combination with immunoenzymatic assay (IgE). However, 
aqueous fluids are seldom available in the laboratory.
We detected specific IgE antibodies in 21 (80.8%) patients with 
toxocariasis using the IB technique, and this finding is considerably 
higher than the positivity found previously in immunological studies of 
toxocariasis by OBWALLER et al.18. This high positivity of the IgE-IB 
technique may be due to the depletion of IgG antibodies beforehand 
with the RF absorbent.
There are few studies on IgA antibodies, even in other parasitic 
infections, however, they have been detected in at least two different 
conditions: (a) in the acute phase of the infection, disappearing 
afterwards, as in toxoplasmosis2 and (b) in the chronic phase, as in 
schistosomiasis mansoni and the digestive form of Chagas disease19, in 
which IgA antibodies last for a long period of time. The latter process 
is not well understood, but when the mucosal lesion is not well resolved 
by the local IgA, it seems that serum IgA antibody levels increase and 
remain elevated for a long period of time. This may be one explanation 
why IgA antibodies were detected in 65.4% of our patients.
To the best of our knowledge, this is the first time that IgA-IB patterns 
have been studied in toxocariasis. The patterns developed by patients 
before treatment were similar to those of IgG-IB, except for the absence 
of high MW bands above 93 kDa, and these results need to be further 
studied. After chemotherapy, the total absence of antibodies to these 
antigenic bands may be associated with therapeutic efficacy.
The overall data demonstrate that antibody isotypes have different IB 
patterns. For diagnosis, IgG is the best marker as it was detected in all 
patients with visceral, ocular and mixed forms of the disease. Low MW 
bands, described by other researchers11,20 as specific, may be targets for 
IgG antibody detection in the diagnosis of toxocariasis. For monitoring 
patients after chemotherapy, IgG to > 205 kDa fractions, IgA to 29-38, 
48-54, 81-93 kDa and IgE to 95-121 kDa may be useful.
The maintenance of specific antibody levels, especially IgG and IgE 
isotypes, observed throughout the follow-up study after chemotherapy 
may be due to factors such as the parasite burden, reinfection or even 
larval reactivation4. These factors may also influence the lack of 
correlation between antibody level decay and time after chemotherapy.
Toxocariasis is a cosmopolitan zoonosis and reliable assays, highly 
sensitive and specific, for diagnosis and therapeutic evaluation are 
required in public health programs. These findings seem promising and 
may provide a framework for investigating further epitopes and represent 
a valuable contribution to immunological markers for diagnosis and 
therapeutic assessment.
RESUMO
Estudo de marcadores imunológicos para o diagnóstico e avaliação 
terapêutica da toxocaríase
Métodos imunológicos desempenham papel importante no 
Table 1 
Follow-up time and specific IgG, IgA and IgE antibody negativity/decay time, 
by immunoblot assay, in 27 patients with toxocariasis
Patient Follow-up time 
(months)
Antibody negativity/decay time (months)
IgG IgA IgE
1 46 * 19 46
2 94 * 28 47
3 37 28 28 NR
4 89 42 20 42
5 98 47 22 22
6 62 * 38 38
7 86 86 NR 86
8 40 * NR NR
9 62 40 19 *
10 51 * * *
11 22 * * *
12 71 64 71 71
13 25 * NR *
14 48 48 48 48
15 61 28 28 28
16 57 * NR NR
17 93 54 54 54
18 68 * 56 *
19 116 64 NR 64
20 27 27 27 27
21 76 76 NR 76
22 57 * 29 *
23 102 22 22 22
24 82 82 NR NR
25 91 73 NR 73
26 48 * NR NR
27 46 * 24 NR
Patients: 1 to 23, visceral form; 24 to 26, mixed visceral and ocular; 27, ocular. 
NR, non-reagent. *Antibody maintenance during follow-up after chemotherapy.
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diagnóstico da toxocaríase, entretanto há poucos estudos sobre 
marcadores diagnósticos e de acompanhamento terapêutico. Foi 
padronizado ensaio de immunoblot (IB) empregando antígeno de 
excreção-secreção de Toxocara canis para pesquisa de anticorpos IgG, 
IgE e IgA em 27 crianças com toxocaríase nas formas visceral (23), mista 
visceral e ocular (3) e ocular (1), por 22-116 meses após quimioterapia. 
Foram observados dois perfis de reatividade dos anticorpos: permanência 
contra todas as frações no decorrer do estudo; diminuição ou negativação 
contra algumas ou todas as frações, porém, essas mudanças não se 
correlacionaram com tempo de tratamento. A sensibilidade do IB foi 
100,0% para anticorpos IgG específicos para frações de massa molecular 
de 29-38, 48-54, 95-116, 121-162, > 205 kDa, 80,8% para IgE específicos 
para 29-38, 48-54, 95-121, > 205 kDa e 65,4% para IgA específicos para 
29-38, 48-54, 81-93 kDa. Anticorpos IgG específicos para frações de 
baixa MM (29-38 e 48-54 kDa) podem ser sugeridos como candidatos a 
marcadores diagnósticos. Por sua vez, anticorpos IgG para fração > 205 
kDa, IgA para 29-38, 48-54, 81-93 kDa e IgE para 95-121 kDa podem 
ser candidatos a marcadores terapêuticos. A identificação de epítopos 
antigênicos relacionados a estes marcadores poderá ser importante 
para o desenvolvimento de ensaios altamente sensíveis e específicos no 
diagnóstico e avaliação terapêutica da toxocaríase.
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